scholarly journals The Maize Unstable factor for orange1 Is a Dominant Epigenetic Modifier of a Tissue Specifically Silent Allele of pericarp color1

Genetics ◽  
2003 ◽  
Vol 163 (3) ◽  
pp. 1135-1146 ◽  
Author(s):  
Surinder Chopra ◽  
Suzy M Cocciolone ◽  
Shaun Bushman ◽  
Vineet Sangar ◽  
Michael D McMullen ◽  
...  

Abstract We have characterized Unstable factor for orange1 (Ufo1), a dominant, allele-specific modifier of expression of the maize pericarp color1 (p1) gene. The p1 gene encodes an Myb-homologous transcriptional activator of genes required for biosynthesis of red phlobaphene pigments. The P1-wr allele specifies colorless kernel pericarp and red cobs, whereas Ufo1 modifies P1-wr expression to confer pigmentation in kernel pericarp, as well as vegetative tissues, which normally do not accumulate significant amounts of phlobaphene pigments. In the presence of Ufo1, P1-wr transcript levels and transcription rate are increased in kernel pericarp. The P1-wr allele contains approximately six p1 gene copies present in a hypermethylated and multicopy tandem array. In P1-wr Ufo1 plants, methylation of P1-wr DNA sequences is reduced, whereas the methylation state of other repetitive genomic sequences was not detectably affected. The phenotypes produced by the interaction of P1-wr and Ufo1 are unstable, exhibiting somatic mosaicism and variable penetrance. Moreover, the changes in P1-wr expression and methylation are not heritable: meiotic segregants that lack Ufo1 revert to the normal P1-wr expression and methylation patterns. These results demonstrate the existence of a class of modifiers of gene expression whose effects are associated with transient changes in DNA methylation of specific loci.

2003 ◽  
Vol 69 (12) ◽  
pp. 7145-7152 ◽  
Author(s):  
Zhonghua Ma ◽  
Michael A. Yoshimura ◽  
Themis J. Michailides

ABSTRACT Low and high levels of resistance to the benzimidazole fungicides benomyl and thiophanate-methyl were observed in field isolates of Monilinia fructicola, which is the causative agent of brown rot of stone fruit. Isolates that had low levels of resistance (hereafter referred to as LR isolates) and high levels of resistance (hereafter referred to as HR isolates) were also cold and heat sensitive, respectively. Results from microsatellite DNA fingerprints showed that genetic identities among the populations of sensitive (S), LR, and HR isolates were very high (>0.96). Analysis of DNA sequences of theβ -tubulin gene showed that the LR isolates had a point mutation at codon 6, causing a replacement of the amino acid histidine by tyrosine. Codon 198, which encodes a glutamic acid in S and LR isolates, was converted to a codon for alanine in HR isolates. Based on these point mutations in the β-tubulin gene, allele-specific PCR assays were developed for rapid detection of benzimidazole-resistant isolates of M. fructicola from stone fruit.


2019 ◽  
Vol 18 ◽  
pp. 117693511988051
Author(s):  
Lillian Sun ◽  
Surya Namboodiri ◽  
Emily Chen ◽  
Shuying Sun

DNA methylation plays a significant role in regulating the expression of certain genes in both cancerous and normal breast tissues. It is therefore important to study within-sample co-methylation, ie, methylation patterns between consecutive sites in a chromosome. In this article, we develop 2 new methods to compare co-methylation patterns between normal and cancerous breast samples. In particular, we investigate the co-methylation patterns of 4 different methylation states/levels separately. Using these 2 methods, we focus on addressing the following questions: How often does 1 methylation state change to other methylation states and how is this change dependent on chromosome distance? What co-methylation patterns do normal and cancerous breast samples have? Do genomic sites with different methylation states/levels have different co-methylation patterns? Our results show that cancerous and normal co-methylation patterns are significantly different. We find that this difference exists even when the physical distance of 2 sites are less than 50 bases. Breast cancer cell lines tend to remain in the same methylation state more often than normal samples, especially for the no/low or high/full methylation states. We also find that the co-methylation region lengths for various methylation states (no/low, partial, and high/full methylation states) are very different. For example, the co-methylation region lengths for partial methylation regions are shorter than the unmethylated or fully methylated regions. Our research may provide a deep understanding of co-methylation patterns. These co-methylation patterns will aid in discovering and understanding new methylation events that may be related to novel biomarkers.


Blood ◽  
1989 ◽  
Vol 73 (7) ◽  
pp. 1987-1992 ◽  
Author(s):  
GL Kropp ◽  
S Fucharoen ◽  
SH Embury

Abstract Hemoglobin Constant Spring is an elongation mutation of the alpha 2- globin locus that results in a thalassemic phenotype. It has a high prevalence in Asian populations. When inherited with other alpha- thalassemia determinants, the Constant Spring gene has the potential to cause severe forms of alpha-thalassemia. Accurate diagnosis of the condition with standard hemoglobin electrophoresis is unreliable due to the small to undetectable amounts of the mutant hemoglobin present. Because of the extensive sequence homology of the alpha 1 and alpha 2 loci, allele-specific hybridization to total genomic DNA containing the Constant Spring gene would not distinguish between heterozygous and homozygous hemoglobin Constant Spring. Selective enzymatic amplification of alpha 2-globin DNA sequences, however, allows unambiguous diagnoses to be made using allele-specific hybridization. This method is useful for providing accurate genetic counseling and prenatal diagnosis in populations and specific families in which precise diagnosis is important.


2013 ◽  
Vol 42 (4) ◽  
pp. 2235-2244 ◽  
Author(s):  
Jan O. Haerter ◽  
Cecilia Lövkvist ◽  
Ian B. Dodd ◽  
Kim Sneppen

Abstract Inheritance of 5-methyl cytosine modification of CpG (CG/CG) DNA sequences is needed to maintain early developmental decisions in vertebrates. The standard inheritance model treats CpGs as independent, with methylated CpGs maintained by efficient methylation of hemimethylated CpGs produced after DNA replication, and unmethylated CpGs maintained by an absence of de novo methylation. By stochastic simulations of CpG islands over multiple cell cycles and systematic sampling of reaction parameters, we show that the standard model is inconsistent with many experimental observations. In contrast, dynamic collaboration between CpGs can provide strong error-tolerant somatic inheritance of both hypermethylated and hypomethylated states of a cluster of CpGs, reproducing observed stable bimodal methylation patterns. Known recruitment of methylating enzymes by methylated CpGs could provide the necessary collaboration, but we predict that recruitment of demethylating enzymes by unmethylated CpGs strengthens inheritance and allows CpG islands to remain hypomethylated within a sea of hypermethylation.


Plant Disease ◽  
2014 ◽  
Vol 98 (12) ◽  
pp. 1681-1684 ◽  
Author(s):  
Mavis J. Finger ◽  
Venkatesan Parkunan ◽  
Pingsheng Ji ◽  
Katherine L. Stevenson

Gummy stem blight (GSB), caused by the fungus Didymella bryoniae, is considered the most widespread and destructive disease of watermelon in the southeastern United States. The quinone outside-inhibiting (QoI) fungicide azoxystrobin (AZO), which inhibits mitochondrial respiration by binding to the outer, quinone-oxidizing pocket of the cytochrome bc1 (cyt b) enzyme complex, was initially very effective in controlling GSB. However, resistance to AZO has been observed in D. bryoniae in many watermelon-producing regions. In this study, the DNA sequences of partial cyt b genes of four AZO-resistant (AZO-R) and four AZO-sensitive (AZO-S) isolates of D. bryoniae confirmed the amino acid substitution of glycine by alanine at the 143 codon (G143A) in the AZO-R isolates tested. Allele-specific primers were designed to detect the resistant or sensitive allele at codon 143 of the cyt b gene, which amplified a 165-bp polymerase chain reaction (PCR) product from genomic DNA of nine AZO-R and nine AZO-S isolates of D. bryoniae, respectively. The primer pairs did not amplify DNA from other pathogens tested in the study. The results indicated that the PCR assays developed in the study were specific in differentiating AZO-R and AZO-S isolates and could facilitate AZO resistance detection in D. bryoniae.


2020 ◽  
Vol 12 (8) ◽  
pp. 1482-1492
Author(s):  
Xin Wu ◽  
David A Galbraith ◽  
Paramita Chatterjee ◽  
Hyeonsoo Jeong ◽  
Christina M Grozinger ◽  
...  

Abstract Parent-of-origin methylation arises when the methylation patterns of a particular allele are dependent on the parent it was inherited from. Previous work in honey bees has shown evidence of parent-of-origin-specific expression, yet the mechanisms regulating such pattern remain unknown in honey bees. In mammals and plants, DNA methylation is known to regulate parent-of-origin effects such as genomic imprinting. Here, we utilize genotyping of reciprocal European and Africanized honey bee crosses to study genome-wide allele-specific methylation patterns in sterile and reproductive individuals. Our data confirm the presence of allele-specific methylation in honey bees in lineage-specific contexts but also importantly, though to a lesser degree, parent-of-origin contexts. We show that the majority of allele-specific methylation occurs due to lineage rather than parent-of-origin factors, regardless of the reproductive state. Interestingly, genes affected by allele-specific DNA methylation often exhibit both lineage and parent-of-origin effects, indicating that they are particularly labile in terms of DNA methylation patterns. Additionally, we re-analyzed our previous study on parent-of-origin-specific expression in honey bees and found little association with parent-of-origin-specific methylation. These results indicate strong genetic background effects on allelic DNA methylation and suggest that although parent-of-origin effects are manifested in both DNA methylation and gene expression, they are not directly associated with each other.


1994 ◽  
Vol 14 (2) ◽  
pp. 1204-1212
Author(s):  
E J Beecham ◽  
G M Jones ◽  
C Link ◽  
K Huppi ◽  
M Potter ◽  
...  

Using an assay that measures the removal of UV-induced pyrimidine dimers in specific DNA sequences, we have found that the Pvt-1, immunoglobulin H-C alpha (IgH-C alpha), and IgL-kappa loci are poorly repaired in normal B lymphoblasts from plasmacytoma-susceptible BALB/cAnPt mice. Breaksites in these genes are associated with the chromosomal translocations that are found in > 95% of BALB/cAnPt plasmacytomas. In contrast to those from BALB/cAnPt mice, B lymphoblasts from plasmacytoma-resistant DBA/2N mice rapidly repair Pvt-1, IgH-C alpha, and IgL-kappa. Further, (BALB/cAnPt x DBA/2N)F1 hybrids, which are resistant to plasmacytoma development, carry an efficient (DBA/2N-like) repair phenotype. Analysis of allele-specific repair in the IgH-C alpha locus indicates that efficient repair is controlled by dominant, trans-acting factors. In the F1 heterozygotes, these factors promote efficient repair of BALB/cAnPt IgH-C alpha gene sequences. The same sequences are poorly repaired in the BALB/cAnPt parental strain. Analysis of the strand specificity of repair indicates that both strand-selective and nonselective forms of repair determine repair efficiency at the gene level in nonimmortalized murine B lymphoblasts.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4975-4975
Author(s):  
Udo Siebolts ◽  
Haifa Kathrin Al-Ali ◽  
Dietger Niederwieser ◽  
Claudia Wickenhauser

Abstract Abstract 4975 Background The vast majority of mastocytosis patients carry the p.D816V activating point mutation in exon 17 leading to imatinib resistance. In addition, several less common activating kit mutations, at least partially accessible to imatinib, have been described in a minority of systemic and cutaneous mastocytosis. Therefore, exact molecular identification of patients with mastocytosis of uncertain dignitiy is a precondition for diagnostic and therapeutic purposes. However, atypical mast cell infiltrates within the bone marrow biopsies often are very small and microdissection may be hampered by the inconspicuousness of the atypical mast cells. Hence, an appropriate molecular test should exhibit an exceedingly high sensitivity. Methods In an attempt to combine high sensitivity and robustness we created an approach where we adapted the principle of wild-type blocker PCR employing LNA-substituted oligonucleotides and pyrosequencing technique. First, the unique properties of LNA substituted oligonucleotides were employed. As a consequence of their 2′-O, 4′-C methylene bridge and their characteristic bicyclic structure binding affinity is significantly increased, resulting in high melting points. One base mismatch between an LNA oligonucleotide and the complementary strand can lower the melting point 20-30°C, thereby allowing a LNA oligonucleotide to discriminate a one base pair difference between templates and, in contrary, a single base pair mismatch in the normal DNA octomer decreases Tm only by 10°C. In order to allow LNA-substituted oligonucleotides to block amplification of wild-type a mutated form of Taq polymerase, termed the Stoffel fragment was applied. Stoffel fragment is a modified form of AmpliTaq® DNA polymerase lacking intrinsic 5' to 3' exonuclease activity. Employing this methodological setting including the Stoffel fragment, the LNA oligonucleotides and appropriate primer 20 rounds of PCR were performed and an amplicon of 185 bp was received. As demonstrated employing mixtures of assembled DNA sequences keeping the WT or the p.D816V point mutation the WT/D816V ratio turned in favour of the mutated region performing the LNA – Stoffel PCR. Unique in our approach was a second step in which the suchlike amplified PCR product then was adopted in a pyrosequencing assay (Pyromark 24, Qiagen, Hilden, Germany). Results First of all, employing WT DNA sequences and the L1236 cell line, the ability of the blocking LNA oligonucleotides to prevent primer extension on WT-DNA by AmpliTaq® DNA polymerase was excluded. To determine the minimum concentration of blocker necessary to prevent amplification of WT oligonucleotides, we used serial dilutions of the blocking oligonucleotides and revealed that a minimum of 50 mM of blocker was necessary to prevent a highly competitive WT-amplicon. We then analyzed the sensitivity of the assay and spiced assembled DNA sequences keeping the WT or the D816V point mutation. Performing this experiment, 1:105 (0,001%) mutant DNA sequences were definitely detectable performing this assay but not performing conventional pyrosequencing without specific preamplification. In none of the control experiments employing WT DNA a false positive amplicon of the exon 16 D816V region was seen indicating an excellent specifity of the assay. In the pyrograms only light emission peaks >10% were evaluated. To determine the utility of our technique for detecting minority mutations in bone marrow specimen containing few cells or mixed cell populations, we performed the here presented assay on genomic DNA extracted from formalin-fixed, EDTA decalcified paraffin-embedded trephine biopsies. In all 20 trephine biopsies under study, comprising a morphologically established atypical mast cell density from 1 – 15% a clear cut decision of the genomic status was possible. Conclusions Wild-type blocker PCR employing nonextendable LNA oligonucleotides represents an exceedingly sensitive, allele-specific method. In combination with the pyrosequencing technique the here presented assay is highly reliable and reproducible, simple and fast to perform (3 h), facile to interpret and should be equally applicable to other single-base mutations. In bone marrow biopsies mRNA fragments often are highly degradated. Therefore, in contrast to PCR assays performed on cDNA, the here presented assay is ideal suited for the molecular diagnosis of systemic mastocytosis on formalin-fixed tissues. Disclosures Siebolts: Novartis: Research Funding. Al-Ali:Novartis:. Niederwieser:Novartis: Research Funding. Wickenhauser:Novartis: Research Funding.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3916-3916
Author(s):  
Ahad Al Seraihi ◽  
Ana Rio-Machin ◽  
Kiran Tawana ◽  
Csaba Bödör ◽  
Shamzah Araf ◽  
...  

Abstract Background : While myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are considered sporadic hematopoietic stem cell clonal disorders, there are rare occurrences of familial cases (<5%) where two or more individuals within the same family are affected. These high-risk examples are characterised by wide variations in the age of onset, disease latency and outcome between and within families, making their investigation, follow-up and treatment all the more challenging.To date, germline mutations in 11 disease genes have been described, with mutations in the myeloid transcription factor GATA2 representing one of the best-characterised genetic loci predisposing to inherited hematological malignancies. We have noted that within GATA2 families, particularly those segregating a germline p.Thr354Met mutation, there is striking evidence of reduced penetrance. In our example, two first-degree cousins (III.1 and III.3) developed high-risk MDS with monosomy 7 with a third cousin (III.7) presenting with significant leukopenia (monocytopenia [0.1x109/L] and neutropenia [0.8x109/L]). This contrasts with the parental generation (II.1, II.3 and II.5) who all remain hematologically normal and symptom free into their mid-late 60s (Figure 1). We therefore set out to understand these differences in clinical presentation between mutation carriers. Aims:To investigate the molecular mechanisms underlying the variable penetrance and clinical heterogeneity observed in a GATA2-mutated family. Results:Targeted deep-sequencing of 33 genes frequently mutated in MDS/AML revealed a low overall burden of acquired mutations in the symptomatic carriers with no mutations detected in asymptomatic family members. It was noteworthy that an acquired ASXL1 mutation (p.Gly646TrpfsTer12) was identical in all affected individuals (III.1, III.3 and III.7) (Figure 1) although the variant allele frequency was lower (12%) in III.7 and remained stable (range 12-6%) over a 4 year monitoring period. GATA2 expression was lower in III.7 as assessed by quantitative RT-PCR and strikingly this was associated with monoallelic expression of the mutated GATA2 allele with complete loss of the wild-type (WT) allele expression. Temporal analysis of III.7 at yearly intervals demonstrated reactivation of the WT allele 2 years later, coinciding with a marked improvement in hematological parameters (normal monocyte count, neutrophils >1x109/L). These changes in GATA2 expression were not linked to gross changes in methylation, as assessed by methylation specific PCR and bisulphite sequencing, nor acquisition of additional mutations in the WT promoter. Instead, we believe that allele-specific fluctuations in expression are accompanied by changes in chromatin structure at the promoter. Using a SNP (rs1806462 [C/A]) located in the 5'UTR of GATA2, we assessed allele-specific enrichment of H3K4me3 and H3K27me3 chromatin marks by chromatin immunoprecipitation. Sanger sequencing revealed a significant enhancement in the deposition of H3K4me3 activating chromatin mark on the mutated allele compared to the WT allele at diagnosis and this was reversed at later follow-up, correlating with reactivation of the WT allele expression. There were no discernible allele-specific differences in the H3K27me3 mark across the phenotypes at different time-points. Conclusion: Variable penetrance amongst germline mutation carriers is a feature of many families with inherited forms of MDS/AML and this may be related to the nature of secondary genetic events acquired in at-risk individuals. In this study, however, we show that changes in the WT:mutant allele expression ratio as a result of local and allele-specific changes in chromatin deposition may also influence the penetrance of the inherited mutation. Figure 1 Figure 1. Disclosures Cavenagh: Amgen: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau.


Sign in / Sign up

Export Citation Format

Share Document